PDCD1LG2 and neoplasm: In other studies, in addition to causing immunogenic cell death (ICD), oxaliplatin has been found to reduce the expression of programmed death ligand 2 (PD-L2), therefore reducing the immunosuppressive effects of both DCs and tumor cells [70].